Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Trial
NCT02649790Last updated: 12/4/2025
KPTI
Karyopharm Therapeutics Inc.
